|
AU649421B2
(en)
|
1990-05-18 |
1994-05-26 |
Sanofi-Aventis Deutschland Gmbh |
Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
|
|
DE10023486C1
(de)
|
2000-05-09 |
2002-03-14 |
Schering Ag |
Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
|
EP1617840A4
(en)
|
2003-05-01 |
2008-08-20 |
Bristol Myers Squibb Co |
PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS
|
|
ATE556067T1
(de)
|
2003-05-20 |
2012-05-15 |
Ajinomoto Kk |
Modulatoren des vanilloid rezeptors
|
|
US20050004133A1
(en)
|
2003-06-05 |
2005-01-06 |
Makings Lewis R. |
Modulators of VR1 receptor
|
|
WO2005034870A2
(en)
|
2003-10-07 |
2005-04-21 |
Renovis, Inc. |
Amide compounds and ion channel ligands and uses thereof
|
|
WO2005107460A1
(en)
|
2004-04-22 |
2005-11-17 |
Bayer Cropscience Lp |
Method and composition for controlling weeds
|
|
EP1655297A1
(en)
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
|
US7906533B2
(en)
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
|
JP2008519850A
(ja)
|
2004-11-10 |
2008-06-12 |
シンタ ファーマシューティカルズ コーポレーション |
Ｉｌ−１２調節化合物
|
|
JP4988591B2
(ja)
|
2004-12-17 |
2012-08-01 |
イーライ リリー アンド カンパニー |
新規なｍｃｈ受容体アンタゴニスト
|
|
ATE446962T1
(de)
|
2004-12-17 |
2009-11-15 |
Lilly Co Eli |
Thiazolopyridinon-derivate als mch- rezeptorantagonisten
|
|
EP1674467A1
(en)
|
2004-12-22 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
|
|
WO2007058626A1
(en)
|
2005-11-16 |
2007-05-24 |
S*Bio Pte Ltd |
Indazole compounds
|
|
CN102633783A
(zh)
|
2006-02-10 |
2012-08-15 |
转化技术制药公司 |
作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
|
|
GB0606429D0
(en)
|
2006-03-30 |
2006-05-10 |
Novartis Ag |
Organic compounds
|
|
US8008481B2
(en)
|
2006-03-31 |
2011-08-30 |
Ericsson Anna M |
Indazole compounds
|
|
US20080293785A1
(en)
|
2006-04-11 |
2008-11-27 |
Connolly Peter J |
Substituted benzothiazole kinase inhibitors
|
|
NZ575410A
(en)
|
2006-09-07 |
2012-03-30 |
Biogen Idec Inc |
2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives
|
|
CN101594909A
(zh)
|
2006-09-07 |
2009-12-02 |
比奥根艾迪克Ma公司 |
用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
|
|
US20080153810A1
(en)
|
2006-11-15 |
2008-06-26 |
Forest Laboratories Holdings Limited |
Indazole derivatives useful as melanin concentrating receptor ligands
|
|
EP2121621B1
(en)
|
2006-12-08 |
2014-05-07 |
Exelixis Patent Company LLC |
Lxr and fxr modulators
|
|
JP4785881B2
(ja)
|
2007-02-27 |
2011-10-05 |
大塚製薬株式会社 |
医薬
|
|
PE20090365A1
(es)
|
2007-06-14 |
2009-04-04 |
Schering Corp |
Imidazopirazinas como inhibidores de proteina quinasa
|
|
JP5364875B2
(ja)
|
2007-07-16 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類
|
|
WO2009011850A2
(en)
|
2007-07-16 |
2009-01-22 |
Abbott Laboratories |
Novel therapeutic compounds
|
|
US8399448B2
(en)
|
2007-08-08 |
2013-03-19 |
Merck Serono Sa |
6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
|
|
JP5496915B2
(ja)
|
2008-02-13 |
2014-05-21 |
シージーアイ ファーマシューティカルズ，インコーポレーテッド |
６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
|
|
EP2311842A3
(en)
|
2008-06-24 |
2011-07-13 |
Takeda Pharmaceutical Company Limited |
PI3K/M TOR inhibitors
|
|
EP2367598B1
(en)
|
2008-11-19 |
2014-04-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of diacylglycerol acyltransferase
|
|
WO2010071819A1
(en)
|
2008-12-19 |
2010-06-24 |
Schering Corporation |
Bicyclic heterocyclic derivatives and methods of use thereof
|
|
CN102264701A
(zh)
|
2008-12-23 |
2011-11-30 |
霍夫曼-拉罗奇有限公司 |
作为p2x7调节剂的二氢吡啶酮脲
|
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
|
ES2749504T3
(es)
|
2009-10-13 |
2020-03-20 |
Ligand Pharm Inc |
Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
|
|
US8822447B2
(en)
|
2010-04-22 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Indazole compounds useful as ketohexokinase inhibitors
|
|
US20130053382A1
(en)
|
2010-04-30 |
2013-02-28 |
Sunil Paliwal |
Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
|
|
DK2585064T3
(en)
|
2010-06-24 |
2017-07-24 |
Chemocentryx Inc |
C5aR antagonists
|
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
|
|
RU2632900C2
(ru)
|
2010-11-19 |
2017-10-11 |
Лиганд Фармасьютикалс Инкорпорейтед |
Гетероциклические амины и их применение
|
|
HUE029617T2
(en)
|
2010-12-20 |
2017-03-28 |
Merck Serono Sa |
Indazolyl triazole derivatives as IRAK inhibitors
|
|
WO2012142125A2
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
|
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
|
KR20140077963A
(ko)
|
2011-10-20 |
2014-06-24 |
글락소스미스클라인 엘엘씨 |
시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
|
|
GB201119401D0
(en)
|
2011-11-10 |
2011-12-21 |
Ucb Pharma Sa |
Therapeutic agents
|
|
KR101385603B1
(ko)
|
2012-05-17 |
2014-04-21 |
한국원자력의학원 |
벤조티아졸 유도체 및 암 치료를 위한 그의 용도
|
|
WO2014003483A1
(en)
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
EP2914592B1
(en)
|
2012-11-03 |
2017-10-11 |
Boehringer Ingelheim International GmbH |
Inhibitors of cytomegalovirus
|
|
US9168257B2
(en)
|
2013-05-22 |
2015-10-27 |
Children's Hospital Medical Center |
Combination therapy for MDS
|
|
TWI652014B
(zh)
|
2013-09-13 |
2019-03-01 |
美商艾佛艾姆希公司 |
雜環取代之雙環唑殺蟲劑
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
HK1231480A1
(zh)
|
2014-01-10 |
2017-12-22 |
Aurigene Discovery Technologies Limited |
作为irak4抑制剂的吲唑化合物
|
|
IL311677B2
(en)
|
2014-01-13 |
2025-06-01 |
Aurigene Oncology Ltd |
Bicyclic heterocyclyl derivatives as irak4 inhibitors
|
|
MX2016010056A
(es)
|
2014-02-06 |
2016-11-15 |
Abbvie Inc |
6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
|
|
CA2952188A1
(en)
|
2014-06-20 |
2015-12-23 |
Aurigene Discovery Technologies Limited |
Substituted indazole compounds as irak4 inhibitors
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
WO2016174183A1
(en)
|
2015-04-30 |
2016-11-03 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
|
EP3322409A4
(en)
*
|
2015-07-15 |
2019-07-24 |
Aurigene Discovery Technologies Limited |
SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
|
|
CA2992406A1
(en)
|
2015-07-15 |
2017-01-19 |
Aurigene Discovery Technologies Limited |
Indazole and azaindazole compounds as irak-4 inhibitors
|
|
HK1256242A1
(zh)
|
2015-08-04 |
2019-09-20 |
Rigel Pharmaceuticals, Inc. |
吲哚化合物以及制备和使用该化合物的方法
|
|
US20170035881A1
(en)
*
|
2015-10-19 |
2017-02-09 |
Acerta Pharma B.V. |
Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
|
|
US10435396B2
(en)
*
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
|
US20210292843A1
(en)
|
2016-10-28 |
2021-09-23 |
Children's Hospital Medical Center |
Treatment of diseases associated with activated irak
|
|
CN120267671A
(zh)
*
|
2017-03-31 |
2025-07-08 |
奥锐金肿瘤有限公司 |
用于治疗血液病的化合物和组合物
|
|
EP4410377A3
(en)
*
|
2017-10-31 |
2024-11-13 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
AU2019389174A1
(en)
*
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
HRP20231498T1
(hr)
*
|
2019-05-14 |
2024-03-01 |
Les Laboratoires Servier |
Bcl-2 inhibitori za upotrebu u liječenju raka posredovanog bcl-2 koji nosi gly101val mutaciju
|
|
SG11202113356XA
(en)
*
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
PH12022500002A1
(en)
*
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3800188A1
(en)
*
|
2019-10-02 |
2021-04-07 |
Bayer AG |
Substituted pyrazolopyrimidines as irak4 inhibitors
|
|
AU2021321350A1
(en)
|
2020-08-03 |
2023-03-16 |
Curis, Inc. |
Compositions and methods for treating diseases and disorders
|
|
CA3199157A1
(en)
|
2020-11-18 |
2022-05-27 |
Reinhard Von Roemeling |
Methods of treating diseases and disorders
|
|
CA3214747A1
(en)
|
2021-04-08 |
2022-10-13 |
Reinhard Von Roemeling |
Combination therapies for the treatment of cancer
|
|
CA3251930A1
(en)
|
2022-05-11 |
2023-11-16 |
Curis, Inc. |
TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
|